Please login to the form below

Not currently logged in
Email:
Password:

Invokana

This page shows the latest Invokana news and features for those working in and with pharma, biotech and healthcare.

FDA says no to Lilly, Boehringer’s Jardiance in type 1 diabetes

FDA says no to Lilly, Boehringer’s Jardiance in type 1 diabetes

from AstraZeneca’s Farxiga/Forxiga (dapagliflozin) and Johnson &Johnson’s Invokana (canagliflozin).

Latest news

More from news
Approximately 21 fully matching, plus 43 partially matching documents found.

Latest Intelligence

  • Market dynamics, marketing and analytics Market dynamics, marketing and analytics

    Forxiga and Invokana (canagliflozin) appear to be reaching a plateau but at different lower levels. ... In contrast Jardiance and Vipidia are still growing where Jardiance (the 3rd entrant SGLT2) appears to have overtaken Invokana (the 2nd entrant).

  • Interview: Christopher Boulton, AstraZeneca Interview: Christopher Boulton, AstraZeneca

    Forxiga is set to face competition from other SGLT2 inhibitors either recently approved or on the horizon, including Janssen/Mitsubishi Tanabe's Invokana (canagliflozin), Sanofi/Chugai's tofogliflozin and

  • Pharma deals during April 2013 Pharma deals during April 2013

    Clearly the pressure is on, the announcement coming only a month after Johnson &Johnson obtained US approval for its SGLT2 inhibitor—Invokana (canagliflozin). In this deal, Merck gets to extend the

More from intelligence
Approximately 0 fully matching, plus 3 partially matching documents found.

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
OPEN Health

OPEN Health brings together deep scientific knowledge, global understanding, and broad specialist expertise to support our clients in improving health...

Latest intelligence

Webinar:
Securing a future for telehealth with immersive market research insights...
Accelerating patient recruitment in clinical trials with the Clinical Enrolment Managers (CEMs)
How Innovative Trials' global Clinical Enrolment Managers (CEMs) give clinical trial sites the local touch...
Six ways to improve diversity in clinical trials
Diversity is becoming increasingly important as a focus of clinical trials. This whitepaper gives six approaches that could be implemented to help make diversity a bigger focus on your clinical...